Vanadium and Diabetes

Travis Cannell — Mon, 07 Jan 2008 01:50:46 +0000

Research studies have demonstrated that several genes of insulin signaling pathway are involved in the effect of Vanadium treatment of hyperglycemia. (Ref 1)

It has been found that the poly oxovanadium complex exhibits potent antidiabetic activity in diabetes type I and type 2 in mice. (Ref 2)

Studies indicate that the oral vanadyl acetyl acetonate is well tolerated and benefits diabetic osteopathy of rats and improves diabetes related bone disorders particularly by improving the diabetic state. (Ref 3)

Vanadium is a well known anti-diabetic agent which mimics most of the actions of insulin on mature adipocytes. Studies (Ref 4) show a new dimension in vanadium treatment for diabetes due to its novel role in adipogenensis.

Bis oxovanadium (IV) is a new orally active anti-diabetic organic vanadium complex and it has anti-diabetic and insulin-sensitizing effects in diabetic rats, exhibiting the potential to be developed as a new therapeutic agent for type 2 diabetes. (Ref 5)

Bis oxovanadium (IV) is a safe and potent agent for diabetes treatment because it is able to improve carbohydrate metabolism and to reduce oxidative stress. (Ref 6)

Vanadyl sulfate and taurine are two promising agents in the treatment of diabetes related to their antihyperglycemic, antihyperlipemic, and hyperinsulinemic effects. (Ref 7)

An oxovanadium complex has been tested for bioactivity as an insulin enhancing agent and results showed that the complex at specific doses could lower the blood glucose level in STZ-diabetic rats and improve the response to an oral glucose challenge. (Ref

Oxovanadium is proposed to be an orally active complex for treating type I diabetes and type 2 diabetes in animals. (Ref 9)

A review has been done regarding vanadium’s glucose-enhancing potential, its biodistribution, and biomolecular transformation and its mechanism of action in diabetes treatment. (Ref 10)

The diabetes-associated biochemical and morphological alterations in Golgi complexes were investigated and results showed that sodium metavandate affected diabetic rat liver Golgi complexes. (Ref 11)

Insulin-mimetic vanadyl-poly complex is proposed as a novel drug delivery system for treating type 1 diabetic animals and results showed improvement in diabetes as seen by results on oral glucose tolerance test, HbA(1c) levels, and blood pressure. (Ref 13, 14)

Research data indicate immense hypoglycemic activity and reduced toxicity of oxovanadium complex. (Ref 15)

Treatment with Vanadium, a representative of class of anti-diabetic compounds alleviates hyperglycemia and hyperlipidemia. Oral administration of vanadium compounds in animal models and humans does not cause clinical symptoms of hypoglycemia, a common problem for diabetic patients with insulin treatment. (Ref 16)

Studies have showed that vanadyl sulfate trihydrate can inhibit c AMP dependent protein kinase. (Ref 17)

Among several metals, Vanadium has emerged as an extremely potent agent with insulin-like properties. These insulin-like properties have been demonstrated in isolated cells, tissues, different animal models of type 1 an dtype2 diabetes as well as on a limited number of human subjects. Insulin signal mimicry is suggested as a mechanism for the insulin-like effects of Vanadium.